Dupont Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Dupont Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$988	Hold	32,500	–	–	0.05%	22
2026 Q1	$406	Hold	32,500	–	–	﹤0.01%	87
2025 Q4	$884	Hold	32,500	–	–	﹤0.01%	84
2025 Q3	$1.14K	Hold	32,500	–	–	﹤0.01%	86
2025 Q2	$1.24K	Hold	32,500	–	–	﹤0.01%	86
2025 Q1	$2.28K	Hold	32,500	–	–	﹤0.01%	79
2024 Q4	$1.1K	Hold	32,500	–	–	﹤0.01%	89
2024 Q3	$975	Buy	+32,500	New	+$1.88K	﹤0.01%	100

Other funds holding SLXNW

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Dupont Capital Management's SLXNW Position: Q2 2026 in Review

Dupont Capital Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 32,500 shares worth $988. The position accounts for 0.05% of the portfolio, ranked #22.

Dupont Capital Management first reported a position in SLXNW in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.28K in Q1 2025. 3 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

Dupont Capital Management held 32,500 shares of Silexion Therapeutics Warrant worth $988 as of Q2 2026.
Dupont Capital Management left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
Silexion Therapeutics Warrant made up 0.05% of Dupont Capital Management's portfolio in Q2 2026, its #22 holding.
Dupont Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 8 quarters since.
Dupont Capital Management's Silexion Therapeutics Warrant position peaked at $2.28K in Q1 2025.
3 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Dupont Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.